The brokerage expects Bata to record 11% revenue growth withsneaker category (~20% revenues) to outperform formal category.

The brokerage expects Trent to report 40% YoY revenue growth (three-year CAGR: 29%).

For ABFRL, the brokerage expects Lifestyle brands to register 16% YoY growth whereas Pantaloons division is expected to register subdued growth of ~9%.

Marching towards the upper band i.e. 110 afterreclaiming the major moving averages.

Maintaining steady uptrend. The chart patternindicates the prevailing bias to continue.

After failed attempts to reclaim major movingaverages, it has been trading with negative bias.

Promoters held 51.54 per cent stake in the company as of September quarter, while FIIs owned 0 per cent and DIIs 19.5 per cent.

The bank is realigning the distribution to capture the opportunities in various markets.

Asset quality performance has been strong with continuous improvements in slippages and headline asset quality ratios with restructured book being under control at 0.9%.

Going forward, the market share gains from VIL, tariff hikes, wireline – Jiofibre subscriber additions and other digital avenues triggered by 5G rollout should drive growth.

The brokerage expects Infosys to deliver margin on the lower side of its guidance band, with strong growth and reduced dependence on sub-contractors as attrition falls.

Promoters held 61.9 per cent stake in the company as of 30-Sep-2022, while FIIs owned 15.69 per cent, DIIs 11.65 per cent.

Promoters held 67.24 per cent stake in the company as of 30-Sep-2022, while FIIs owned 20.23 per cent, DIIs 6.43 per cent.

The brokerage has reduced Bills cuts/store estimates and consequently FY23/24/25 EPS has changed by 1.3%, -7.3% and 6.8% respectively.

EBITDA margins to expand by 130bps YoY at 16.4%.

The brokerage expects Gross Margins to improve 190bps QoQ/80bps YoY due to flow through of earlier price hikes.

EBITDA margins are likely to show an uptick of 450 bps QoQ to 15.80% due to likely improvement in margins for GCC hospitals.

EBITDA during the quarter is expected at Rs 82 crore, up 9.4% QoQ. EBITDA margins are likely to improve 113 bps QoQ to 18.9%. HCG is expected to post a net profit of Rs 20 crore.

Promoters held 63.85 per cent stake in the company as of 30-Jun-2022, while FIIs owned 14.16 per cent, DIIs 13.71 per cent.

EBITDA margins are expected to improve by 156 bps to 19.9%. Net profit is expected to increase 11.66% QoQ to Rs 21 crore.